RAS Mutations Enhance Chemotherapy in AML
Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission.
Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission. Their relapse rate was 45%, compared with 68% for high-dose patients with normal RAS, according to a CALGB study published online (JCO June 16, 2008). This could allow doctors to identify patients who would benefit from aggressive therapy.
Articles in this issue
National Cancer Survivors Day
New Indication for Velcade in Previously Untreated Myeloma
Risk Factors for Mantle Cell Lymphoma Identified
RAS Mutations Enhance Chemotherapy in AML
Antidiabetic Agent Metformin May Boost pCRs in Breast Ca
Eisai Seeks Full FDA Approval for Ontak for CTCL
Symptom Screen Plus CA125 Detects Early Ovarian Ca
Cisplatin Linked to Cardiac Complications in Testicular Ca Patients
Updated X-ACT Study Results Presented
ThromboGenics and BioInvent Announce Alliance with Roche
Gene Signature Identifies Low-Risk Patients in MAGE-A3 Trial
p110-Beta Drives Cancer Growth When PTEN is Inhibited, Animal Study Shows
Proton beam RT not exempt from evidence-based medicine
Investigational Agents May be Effective for Resistant GIST
Coverage vs Cost-Cutting: A look Inside the Obama and McCain Healthcare Plans
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
